Cabaletta Bio, Inc. announced new clinical data from the first 10 patients treated with their therapy rese-cel, showing promising results in autoimmune diseases, including significant improvements in patients with dermatomyositis, systemic lupus erythematosus, and systemic sclerosis. The company is conducting multiple Phase 1/2 trials and aims to develop a targeted cell therapy for autoimmune conditions.